Triomics offers an oncology-specific AI platform that automates chart review, clinical trial matching, appointment prep and submission of tumor reports to government registries. The company added verifiable patient summaries that surface key information inside clinicians' existing tools without requiring application switching. Triomics built its models and product specifically for oncology data, and counts institutions like Memorial Sloan Kettering and Yale Cancer Center as users. Founded in 2021, the startup expanded its platform as LLM capabilities advanced and reports rapid commercial traction. Over the past year it grew its enterprise customer base fourfold and achieved a tenfold increase in annualized recurring revenue. The company faces competition from AI medical scribe products such as Abridge and Microsoft's Nuance.

Total raised

$37M

Funding rounds

2

Latest round

Series B

Latest activity

May 2026